Literature DB >> 22809906

Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients.

Nathalie Layios1, Bernard Lambermont, Jean-Luc Canivet, Philippe Morimont, Jean-Charles Preiser, Christophe Garweg, Didier Ledoux, Frédéric Frippiat, Sonia Piret, Jean-Baptiste Giot, Patricia Wiesen, Christelle Meuris, Paul Massion, Philippe Leonard, Monique Nys, Patrizio Lancellotti, Jean-Paul Chapelle, Pierre Damas.   

Abstract

OBJECTIVES: To test the usefulness of procalcitonin serum level for the reduction of antibiotic consumption in intensive care unit patients.
DESIGN: Single-center, prospective, randomized controlled study.
SETTING: Five intensive care units from a tertiary teaching hospital. PATIENTS: All consecutive adult patients hospitalized for >48 hrs in the intensive care unit during a 9-month period.
INTERVENTIONS: Procalcitonin serum level was obtained for all consecutive patients suspected of developing infection either on admission or during intensive care unit stay. The use of antibiotics was more or less strongly discouraged or recommended according to the Muller classification. Patients were randomized into two groups: one using the procalcitonin results (procalcitonin group) and one being blinded to the procalcitonin results (control group). The primary end point was the reduction of antibiotic use expressed as a proportion of treatment days and of daily defined dose per 100 intensive care unit days using a procalcitonin-guided approach. Secondary end points included: a posteriori assessment of the accuracy of the infectious diagnosis when using procalcitonin in the intensive care unit and of the diagnostic concordance between the intensive care unit physician and the infectious-disease specialist.
MEASUREMENTS AND MAIN RESULTS: There were 258 patients in the procalcitonin group and 251 patients in the control group. A significantly higher amount of withheld treatment was observed in the procalcitonin group of patients classified by the intensive care unit clinicians as having possible infection. This, however, did not result in a reduction of antibiotic consumption. The treatment days represented 62.6±34.4% and 57.7±34.4% of the intensive care unit stays in the procalcitonin and control groups, respectively (p=.11). According to the infectious-disease specialist, 33.8% of the cases in which no infection was confirmed, had a procalcitonin value>1µg/L and 14.9% of the cases with confirmed infection had procalcitonin levels<0.25 µg/L. The ability of procalcitonin to differentiate between certain or probable infection and possible or no infection, upon initiation of antibiotic treatment was low, as confirmed by the receiving operating curve analysis (area under the curve=0.69). Finally, procalcitonin did not help improve concordance between the diagnostic confidence of the infectious-disease specialist and the ICU physician.
CONCLUSIONS: Procalcitonin measuring for the initiation of antimicrobials did not appear to be helpful in a strategy aiming at decreasing the antibiotic consumption in intensive care unit patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809906     DOI: 10.1097/CCM.0b013e318251517a

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  45 in total

1.  Procalcitonin for antibiotic treatment in intensive care unit patients.

Authors:  Nathalie Layios; Bernard Lambermont
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

2.  Implementation of a procalcitonin-guided algorithm for antibiotic therapy in the burn intensive care unit.

Authors:  A Lavrentieva; P Kontou; V Soulountsi; J Kioumis; O Chrysou; M Bitzani
Journal:  Ann Burns Fire Disasters       Date:  2015-09-30

Review 3.  Antibiotic stewardship programmes in intensive care units: Why, how, and where are they leading us.

Authors:  Yu-Zhi Zhang; Suveer Singh
Journal:  World J Crit Care Med       Date:  2015-02-04

Review 4.  De-escalating Antibiotic Use in the Inpatient Setting: Strategies, Controversies, and Challenges.

Authors:  J Daniel Markley; Shaina Bernard; Gonzalo Bearman; Michael P Stevens
Journal:  Curr Infect Dis Rep       Date:  2017-04       Impact factor: 3.725

5.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

Review 6.  Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Authors:  Brenda Ng Andriolo; Regis B Andriolo; Reinaldo Salomão; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2017-01-18

Review 7.  Sepsis outside intensive care unit: the other side of the coin.

Authors:  F Mearelli; D Orso; N Fiotti; N Altamura; A Breglia; M De Nardo; I Paoli; M Zanetti; C Casarsa; G Biolo
Journal:  Infection       Date:  2014-08-11       Impact factor: 3.553

Review 8.  Rationalizing antimicrobial therapy in the ICU: a narrative review.

Authors:  Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier
Journal:  Intensive Care Med       Date:  2019-01-18       Impact factor: 17.440

Review 9.  Procalcitonin: Where Are We Now?

Authors:  Bachar Hamade; David T Huang
Journal:  Crit Care Clin       Date:  2019-10-21       Impact factor: 3.598

10.  [Bacteremia and sepsis].

Authors:  S Hagel; M W Pletz; F M Brunkhorst; H Seifert; W V Kern
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.